Cargando…

Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas

SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (<5%). In the last decades, the concomitant use of two non-invasive, electromagnetic devices, modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) has been introduced. Both...

Descripción completa

Detalles Bibliográficos
Autores principales: Szasz, Attila Marcell, Arrojo Alvarez, Elisabeth Estefanía, Fiorentini, Giammaria, Herold, Magdolna, Herold, Zoltan, Sarti, Donatella, Dank, Magdolna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913117/
https://www.ncbi.nlm.nih.gov/pubmed/36765840
http://dx.doi.org/10.3390/cancers15030880
_version_ 1784885348141105152
author Szasz, Attila Marcell
Arrojo Alvarez, Elisabeth Estefanía
Fiorentini, Giammaria
Herold, Magdolna
Herold, Zoltan
Sarti, Donatella
Dank, Magdolna
author_facet Szasz, Attila Marcell
Arrojo Alvarez, Elisabeth Estefanía
Fiorentini, Giammaria
Herold, Magdolna
Herold, Zoltan
Sarti, Donatella
Dank, Magdolna
author_sort Szasz, Attila Marcell
collection PubMed
description SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (<5%). In the last decades, the concomitant use of two non-invasive, electromagnetic devices, modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) has been introduced. Both mEHT and TTF have specific anti-tumor effects, which can help to achieve a more efficient treatment of patients and a higher rate of therapeutic response. In this meta-analysis we investigated how patient survival rates change if either device is used. The significant difference in the 1-year survival rates between the treated (>60%) and untreated groups (historical data: <40%) confirms the observation that the use of both mEHT and TTF in the treatment of glioblastomas benefits patients. In addition, it is important to emphasize that most studies have proven that the mEHT or TTF-treated patients’ quality of life is much better than that of the untreated patients. ABSTRACT: Background: Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects. Methods: A meta-analysis of randomized and observational studies about mEHT and TTF was conducted. Results: A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25–59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32–89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53–81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%, p = 0.0021; mEHT studies after 2008: 73% vs. 54%, p = 0.4214; TTF studies: 83% vs. 52%, p = 0.0083), compared with recurrent glioblastoma. Conclusions: Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases.
format Online
Article
Text
id pubmed-9913117
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99131172023-02-11 Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas Szasz, Attila Marcell Arrojo Alvarez, Elisabeth Estefanía Fiorentini, Giammaria Herold, Magdolna Herold, Zoltan Sarti, Donatella Dank, Magdolna Cancers (Basel) Systematic Review SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (<5%). In the last decades, the concomitant use of two non-invasive, electromagnetic devices, modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) has been introduced. Both mEHT and TTF have specific anti-tumor effects, which can help to achieve a more efficient treatment of patients and a higher rate of therapeutic response. In this meta-analysis we investigated how patient survival rates change if either device is used. The significant difference in the 1-year survival rates between the treated (>60%) and untreated groups (historical data: <40%) confirms the observation that the use of both mEHT and TTF in the treatment of glioblastomas benefits patients. In addition, it is important to emphasize that most studies have proven that the mEHT or TTF-treated patients’ quality of life is much better than that of the untreated patients. ABSTRACT: Background: Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects. Methods: A meta-analysis of randomized and observational studies about mEHT and TTF was conducted. Results: A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25–59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32–89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53–81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%, p = 0.0021; mEHT studies after 2008: 73% vs. 54%, p = 0.4214; TTF studies: 83% vs. 52%, p = 0.0083), compared with recurrent glioblastoma. Conclusions: Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases. MDPI 2023-01-31 /pmc/articles/PMC9913117/ /pubmed/36765840 http://dx.doi.org/10.3390/cancers15030880 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Szasz, Attila Marcell
Arrojo Alvarez, Elisabeth Estefanía
Fiorentini, Giammaria
Herold, Magdolna
Herold, Zoltan
Sarti, Donatella
Dank, Magdolna
Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
title Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
title_full Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
title_fullStr Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
title_full_unstemmed Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
title_short Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
title_sort meta-analysis of modulated electro-hyperthermia and tumor treating fields in the treatment of glioblastomas
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913117/
https://www.ncbi.nlm.nih.gov/pubmed/36765840
http://dx.doi.org/10.3390/cancers15030880
work_keys_str_mv AT szaszattilamarcell metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas
AT arrojoalvarezelisabethestefania metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas
AT fiorentinigiammaria metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas
AT heroldmagdolna metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas
AT heroldzoltan metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas
AT sartidonatella metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas
AT dankmagdolna metaanalysisofmodulatedelectrohyperthermiaandtumortreatingfieldsinthetreatmentofglioblastomas